Kenvue (NYSE:KVUE) Given New $19.00 Price Target at Citigroup
by Jessica Moore · The Cerbat GemKenvue (NYSE:KVUE – Get Free Report) had its price target reduced by analysts at Citigroup from $20.00 to $19.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Citigroup’s price objective suggests a potential upside of 9.79% from the company’s previous close.
Several other brokerages also recently issued reports on KVUE. Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday. UBS Group lowered their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a report on Tuesday, April 7th. Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Argus upgraded Kenvue to a “hold” rating in a report on Friday, March 6th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a report on Wednesday, April 8th. Three analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $19.33.
Get Our Latest Stock Analysis on KVUE
Kenvue Trading Down 0.4%
NYSE KVUE traded down $0.08 on Wednesday, reaching $17.31. The company had a trading volume of 5,103,409 shares, compared to its average volume of 38,149,070. The stock’s 50 day moving average is $17.96 and its 200-day moving average is $17.08. The stock has a market cap of $33.22 billion, a price-to-earnings ratio of 22.47, a PEG ratio of 3.92 and a beta of 0.61. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. Kenvue has a 52 week low of $14.02 and a 52 week high of $25.17.
Kenvue (NYSE:KVUE – Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $3.68 billion. During the same quarter in the prior year, the company posted $0.26 earnings per share. The firm’s revenue was up 3.2% on a year-over-year basis. Equities analysts predict that Kenvue will post 1.14 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Kenvue by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock worth $4,052,913,000 after buying an additional 1,604,040 shares in the last quarter. State Street Corp grew its holdings in shares of Kenvue by 3.5% during the fourth quarter. State Street Corp now owns 118,865,134 shares of the company’s stock worth $2,050,424,000 after buying an additional 4,063,257 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Kenvue by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock worth $856,778,000 after buying an additional 371,322 shares in the last quarter. Independent Franchise Partners LLP grew its holdings in shares of Kenvue by 56.3% during the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock worth $830,527,000 after buying an additional 17,343,785 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Kenvue during the fourth quarter worth about $756,862,000. 97.64% of the stock is currently owned by institutional investors.
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.